Jasper Therapeutics, Inc. (JSPR) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.69
↓-42% vs avg
5yr avg: 2.93
30Y Low0.5·High6.8
ROE
↓
-230.3%
↑-66% vs avg
5yr avg: -138.9%
30Y Low-230%·High-24%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
JSPR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Jasper Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $7M | $28M | $312M | $82M | $18M | $89M | $17M | — |
| Enterprise Value | $-20019824 | $604150 | $242M | $-1737022 | $-16978484 | $8M | $-898502 | — |
| P/E Ratio → | -0.12 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.69 | 6.76 | 5.06 | 1.05 | 0.49 | 1.29 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
JSPR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
JSPR Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -230.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -230.3% | -230.3% | -101.7% | -112.7% | -71.4% | -178.2% | — | -23.6% |
| ROA | -131.1% | -131.1% | -81.5% | -90.0% | -53.1% | -52.4% | -125.3% | -18.3% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -184.6% | -184.6% | -103.6% | -111.2% | -80.7% | -70.2% | -92.8% | -18.7% |
JSPR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $29M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.30 | 0.30 | 0.03 | 0.04 | 0.10 | 0.04 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -6.61 | -1.13 | -1.07 | -0.96 | -1.18 | — | -1.29 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($29M) exceeds total debt ($1M)
JSPR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Jasper Therapeutics, Inc.'s current ratio of 2.62x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 7.19x to 2.62x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.62 | 2.62 | 4.98 | 7.19 | 5.91 | 10.95 | 5.16 | 13.63 |
| Quick Ratio | 2.62 | 2.62 | 4.98 | 7.19 | 5.91 | 10.95 | 5.16 | 13.63 |
| Cash Ratio | 2.17 | 2.17 | 4.70 | 7.02 | 5.41 | 10.56 | 4.94 | 13.63 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
JSPR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Jasper Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $15M | $15M | $10M | $4M | $1M | $172982 | $176000 |
Peer Comparison
Compare JSPR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 JSPRYou | $7M | -0.1 | — | — | — | — | -230.3% | — | — |
 BEAM | $3B | -35.8 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $245M | -1.4 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 CRSP | $5B | -7.7 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $1B | -3.2 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 FATE | $240M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 SGMO | $65M | -0.4 | — | — | 80.8% | -273.1% | -2891.8% | -5405.6% | — |
 IONS | $12B | -30.8 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 RCKT | $300M | -1.4 | — | — | — | — | -60.3% | -62.4% | — |
 ADMA | $2B | 13.7 | 9.5 | 68.4 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in JSPR 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in JSPR be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs JSPR Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationJSPR vs BEAM — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Beam Therapeutics Inc..
Compare NowJSPR — Frequently Asked Questions
Quick answers to the most common questions about buying JSPR stock.
What is Jasper Therapeutics, Inc.'s P/E ratio?
Jasper Therapeutics, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Jasper Therapeutics, Inc.'s ROE?
Jasper Therapeutics, Inc.'s return on equity (ROE) is -230.3%. The historical average is -119.7%.
Is JSPR stock overvalued?
Based on historical data, Jasper Therapeutics, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.